Gilde Healthcare Partners

Gilde Healthcare runs two separate but complementary fund strategies. The Venture fund series invests in early- to mid-stage companies developing therapeutics, medical devices, and digital health products across Europe and North America, with a strong focus on the Boston-Cambridge life-sciences cluster. The Growth fund series targets profitable, fast-growing European healthcare-services and medical-device companies, typically with EBITDA above EUR 5 million. This structure allows the firm to underwrite both binary clinical-stage risk and stable cash-flow businesses within the same partnership.

The firm operates a transatlantic model with a deliberate geographic split. Venture capital investments concentrate on the US — particularly the Boston-Cambridge corridor — and the Benelux region. Growth equity and lower-mid-market buyouts focus on Germany, Switzerland, and the Nordic countries, where the firm sees strong medical-technology clusters and profitable healthcare-services businesses. The firm maintains offices in Utrecht, Amsterdam, Frankfurt, and Boston to support this coverage.

Gilde Healthcare Partners was originally part of Gilde Investment, a Dutch private equity franchise established in the 1980s. The healthcare unit was spun out as a dedicated specialist firm in 2000 under the leadership of Edwin de Graaf and Pieter van der Meer. While the separation from Gilde Investment is now complete, the healthcare arm retains the 'Gilde' name and a shared heritage, though it operates independently with its own fund structures, investment committees, and limited partner base.

The firm covers a wide spectrum. On the venture side, it invests from seed-stage through Series B in therapeutics, medical devices, and digital health. On the growth side, it targets later-stage, profitable companies in healthcare services and medtech — often family-founded or founder-led businesses seeking a partner for international expansion or acquisition-led growth. The firm does not pursue large-cap buyouts or pure real-estate healthcare deals.

Yes, the Venture fund actively invests in therapeutics companies with preclinical or clinical-stage assets, particularly those addressing high-unmet-need indications. The firm's European and US venture teams have backed companies developing small-molecule drugs, biologics, and gene therapies. This early-stage, high-risk exposure is balanced by the cash-flow-generating investments in the Growth fund, creating a portfolio-level risk-management architecture.

The firm's most recent venture fund, Gilde Healthcare Venture VI, closed at EUR 418 million in 2021 with commitments from European institutional investors, development banks, family offices, and fund-of-funds (per the firm, 2021). The LP base reflects the firm's long track record in European healthcare and its ability to attract both return-seeking institutional capital and mission-aligned development-finance institutions interested in health-system innovation.

Gilde Healthcare primarily leads or co-leads its rounds and does not operate a formal co-investment club for external LPs alongside its fund commitments. The firm occasionally partners with other specialist healthcare investors on larger growth-equity transactions or cross-border deals, particularly when combining US venture expertise with European commercial-stage scaling capabilities. It does not operate as a fund-of-funds or syndicate aggregator.